EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Calcium‐Based Antimicrobial Peptide Compounds as a Novel Treatment for Chronic Cheilitis: A Controlled Clinical Trial

Hyunsuk Ji, Tao Cai, Shuang Chen, Jianxia Xiong, Siyuan Geng, Aldi Dayu Saputra

Journal of Cosmetic Dermatology · 2026-11 · 25 (11)

DOI: 10.1111/jocd.71239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 08.11.2026. Verfasst von Hyunsuk Ji und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic cheilitis refers to recurrent inflammation of the lips lasting for 3 months or longer. Commonly managed with topical corticosteroids or tacrolimus; however, these medications carry a risk of side effects. Calcium‐based antimicrobial peptide compounds (CAPCS) contain natural calcium derivatives and antimicrobial peptides that provide anti‐inflammatory and barrier‐supporting effects. We explored whether CAPCS lip balm could serve as an alternative to tacrolimus 0.03% for treating chronic cheilitis.

Methods

A total of 52 patients with chronic cheilitis participated in this double‐blind, controlled trial and were allocated to use CAPCS lip balm ( n = 26) or 0.03% tacrolimus ointment ( n = 26) for a period of 4 weeks. Clinical assessments were performed at baseline, Week 2, and Week 4. A 3‐month follow‐up visit was conducted to evaluate recurrence or sustained improvement.

Results

Forty‐five patients completed the 4‐week treatment. Both groups showed marked improvement from baseline by Week 4 ( p < 0.001), although the tacrolimus group showed a faster reduction at Week 2 (4.4 ± 4.3 vs. 6.7 ± 4.0, p = 0.028). CAPCS showed good tolerability, with two cases of mild adverse events (7.7%), in contrast to six events (23.1%) observed in the tacrolimus group. At the 3‐month follow‐up, patients who continued CAPCS use showed sustained improvement, while recurrence was more common among those who stopped treatment.

Conclusions

CAPCS lip balm demonstrated comparable efficacy to tacrolimus 0.03% ointment, was better tolerated, and may serve as a safe alternative or a maintenance option for chronic cheilitis.

Zitieren

APA

Ji, H., Cai, T., Chen, S., Xiong, J., Geng, S., & Saputra, A. D. (2026). Calcium‐Based Antimicrobial Peptide Compounds as a Novel Treatment for Chronic Cheilitis: A Controlled Clinical Trial. Journal of Cosmetic Dermatology, 25(11). https://doi.org/10.1111/jocd.71239

Vancouver

Ji H, Cai T, Chen S, Xiong J, Geng S, Saputra AD. Calcium‐Based Antimicrobial Peptide Compounds as a Novel Treatment for Chronic Cheilitis: A Controlled Clinical Trial. Journal of Cosmetic Dermatology. 2026;25(11). doi:10.1111/jocd.71239

BibTeX
@article{Ji2026,
  author = {Ji, Hyunsuk and Cai, Tao and Chen, Shuang and Xiong, Jianxia and Geng, Siyuan and Saputra, Aldi Dayu},
  title = {Calcium‐Based Antimicrobial Peptide Compounds as a Novel Treatment for Chronic Cheilitis: A Controlled Clinical Trial},
  journal = {Journal of Cosmetic Dermatology},
  year = {2026},
  volume = {25},
  number = {11},
  doi = {10.1111/jocd.71239}
}
Kostenlos starten →